Could Regeneron’s Antibody Therapy Be as Important as Vaccines in Fighting COVID?

1 min read

Regeneron Pharmaceuticals (NASDAQ: REGN) recently announced overwhelmingly positive results from a late-stage study of its antibody cocktail therapy in treating individuals infected with COVID-19. In this Motley Fool Live video recorded on March 24, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Regeneron’s therapy could be as important as vaccines in the fight against COVID-19.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

What’s Behind Harvest Health’s Mixed Q4 Results

Next Story

1 FAANG Stock to Buy Right Now and 1 to Avoid

Latest from Blog